DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the…